Skip to main content
Top

2021 | OriginalPaper | Hoofdstuk

24. Mammacarcinoom

Auteurs : C. M. R. Haekens, M. V. C. Widdershoven, MANP, Dr. E. M. Heuts

Gepubliceerd in: Leerboek oncologieverpleegkunde

Uitgeverij: Bohn Stafleu van Loghum

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

Het mammacarcinoom komt in Nederland veel voor. Het is de tweede doodsoorzaak door kanker bij de Nederlandse vrouw; 20 % van de borstkankerpatiënten is jonger dan 50 jaar en meer dan 70 % van de patiënten is jonger dan 70. De incidentie van het mammacarcinoom neemt per jaar toe met ongeveer 1–2 %, maar ondanks dit feit neemt de sterfte aan borstkanker af. Dit is mede te danken aan vroegdiagnostiek en verbeterde adjuvante behandelingen. Ongeveer 120 mannen per jaar krijgen borstkanker. Bij het ontstaan van het mammacarcinoom speelt waarschijnlijk een combinatie van hormonale, erfelijke en omgevingsfactoren een rol. Door het inzetten van genetisch onderzoek kunnen genmutatiedragers worden opgespoord en kan een behandeling op maat worden aangeboden. Door de snelle ontwikkeling op het gebied van moleculair-genetisch onderzoek kan in toenemende mate ook doelgerichte therapie worden ingezet. Reconstructieve mammachirurgie is tegenwoordig niet meer weg te denken uit het behandelingsaanbod bij mammacarcinoom, met positieve gevolgen voor de kwaliteit van leven. Lobulaire carcinomen metastaseren vaker dan ductale carcinomen. Palliatieve behandeling is in eerste instantie gericht op het verbeteren of handhaven van de kwaliteit van leven. De mammacareverpleegkundige of verpleegkundig specialist speelt een belangrijke rol in de voorlichting, begeleiding, nazorg en in de logistiek van het behandeltraject.
Literatuur
go back to reference Amin, M., Edge, S., Greene, F., Byrd, D., Brookland, R., Washington, M., & Meyer, L. (2017). AJCC cancer, staging manual. Berlin: Springer International Publishing.CrossRef Amin, M., Edge, S., Greene, F., Byrd, D., Brookland, R., Washington, M., & Meyer, L. (2017). AJCC cancer, staging manual. Berlin: Springer International Publishing.CrossRef
go back to reference Beugels, J., Kool, M., Hoekstra, L. T., Heuts, E. M., Tuinder, S. M. H., Van der Hulst, R. R. W. J., & Piatkowski, A. (2018). Quality of life of patients after immediate or delayed autologous breast reconstruction: a multicenter study. Annals of Plastic Surgery, 5, 523–527.CrossRef Beugels, J., Kool, M., Hoekstra, L. T., Heuts, E. M., Tuinder, S. M. H., Van der Hulst, R. R. W. J., & Piatkowski, A. (2018). Quality of life of patients after immediate or delayed autologous breast reconstruction: a multicenter study. Annals of Plastic Surgery, 5, 523–527.CrossRef
go back to reference Bijkerk, E., Van Kuijk, S. M. J., Beugels, J., Cornelissen, A. J. M., Heuts, E. M., Van der Hulst, R. R. W. J., & Tuinder, S. M. H. (2019). Breast sensibility after mastectomy and implant-based breast reconstruction. Breast Cancer Research and Treatment, 2, 369–378.CrossRef Bijkerk, E., Van Kuijk, S. M. J., Beugels, J., Cornelissen, A. J. M., Heuts, E. M., Van der Hulst, R. R. W. J., & Tuinder, S. M. H. (2019). Breast sensibility after mastectomy and implant-based breast reconstruction. Breast Cancer Research and Treatment, 2, 369–378.CrossRef
go back to reference Blok, E. J., Meershoek-Klein-Kranenburg, E., Duijm-de Carpentier, M., Putter, H., Van den Bosch, J., Maartense, E., et al. (2017). Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the ideal trial. Journal of the National Cancer Institute, 110(1). Blok, E. J., Meershoek-Klein-Kranenburg, E., Duijm-de Carpentier, M., Putter, H., Van den Bosch, J., Maartense, E., et al. (2017). Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the ideal trial. Journal of the National Cancer Institute, 110(1).
go back to reference Brands-Appeldoorn, A. T. P. M., Maaskant-Braat, A. J. G., Zwaans, W. A. R., Dieleman, J. P., Schenk, K. E., Broekhuysen, C. L., et al. (2018). Patient-reported outcome measurement compared with professional judgment of cosmetic results after breast-conserving therapy. Current Oncology, 6, e553–e561.CrossRef Brands-Appeldoorn, A. T. P. M., Maaskant-Braat, A. J. G., Zwaans, W. A. R., Dieleman, J. P., Schenk, K. E., Broekhuysen, C. L., et al. (2018). Patient-reported outcome measurement compared with professional judgment of cosmetic results after breast-conserving therapy. Current Oncology, 6, e553–e561.CrossRef
go back to reference Burstein, H. J., Lacchetti, C., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. E., et al. (2016). Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. American society of clinical oncology clinical practice guideline update on ovarian suppression. Journal of Clinical Oncology, 14, 1689–1701.CrossRef Burstein, H. J., Lacchetti, C., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. E., et al. (2016). Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. American society of clinical oncology clinical practice guideline update on ovarian suppression. Journal of Clinical Oncology, 14, 1689–1701.CrossRef
go back to reference Colleoni, M., Sun, Z., Price, K. N., Karlsson, P., Forbes, J. F., Thurlimann, B., et al. (2016). Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: Results from the international breast cancer study group trials I to V. Journal of Clinical Oncology, 9, 927–935.CrossRef Colleoni, M., Sun, Z., Price, K. N., Karlsson, P., Forbes, J. F., Thurlimann, B., et al. (2016). Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: Results from the international breast cancer study group trials I to V. Journal of Clinical Oncology, 9, 927–935.CrossRef
go back to reference Darby, S., McGale, P., Correa, C., Taylor, C., Arriagada, R., Clarke, M., et al. (2011). Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet, 378, 1707–1716.CrossRef Darby, S., McGale, P., Correa, C., Taylor, C., Arriagada, R., Clarke, M., et al. (2011). Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet, 378, 1707–1716.CrossRef
go back to reference Early Breast Cancer Trialists’ Collaborative Group (EBCTG). (2005). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet, 366, 2087–2106.CrossRef Early Breast Cancer Trialists’ Collaborative Group (EBCTG). (2005). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet, 366, 2087–2106.CrossRef
go back to reference Ecclestone, C., Chow, R., Pulenzas, N., Zhang, L., Leahey, A., Hamer, J., et al. (2016). Quality of life and symptom burden in patients with metastatic breast cancer. Supportive Care in Cancer, 29, 4035–4043.CrossRef Ecclestone, C., Chow, R., Pulenzas, N., Zhang, L., Leahey, A., Hamer, J., et al. (2016). Quality of life and symptom burden in patients with metastatic breast cancer. Supportive Care in Cancer, 29, 4035–4043.CrossRef
go back to reference Henneghan, A., Phillips, C., & Courtney, A. (2018). We are different: Young adult survivors’ experience of breast cancer. The Breast Journal, 6, 1126–1128.CrossRef Henneghan, A., Phillips, C., & Courtney, A. (2018). We are different: Young adult survivors’ experience of breast cancer. The Breast Journal, 6, 1126–1128.CrossRef
go back to reference Lauby-Secretan, B., Scoccianti, C., Loomis, D., Benbrahim-Tallaa, L., Bouvard, V., Bianchini, F., & Straif, K. (2015). Breast-cancer screening; Viewpoint of the IARC Working Group. New England Journal of Medicine, 24, 2353–2558. Lauby-Secretan, B., Scoccianti, C., Loomis, D., Benbrahim-Tallaa, L., Bouvard, V., Bianchini, F., & Straif, K. (2015). Breast-cancer screening; Viewpoint of the IARC Working Group. New England Journal of Medicine, 24, 2353–2558.
go back to reference Lischalk, J. W., Chen, H., Repka, M. C., Campbell, L. D., Obayomi-Davies, O., Katarina, S., et al. (2018). Definitive hypofractionated radiation therapy for early stage breast cancer: Dosimetric feasibility of stereotactic ablative radiotherapy and proton beam therapy for intact breast tumors. Advances in Radiation Oncology, 3, 447–457.CrossRef Lischalk, J. W., Chen, H., Repka, M. C., Campbell, L. D., Obayomi-Davies, O., Katarina, S., et al. (2018). Definitive hypofractionated radiation therapy for early stage breast cancer: Dosimetric feasibility of stereotactic ablative radiotherapy and proton beam therapy for intact breast tumors. Advances in Radiation Oncology, 3, 447–457.CrossRef
go back to reference Lobbezoo, D. J. A., Van Kampen, R. J. W., Voogd, A. C., Dercksen, M. W., Van den Berkmortel, F., Smilde, T. J., et al. (2013). Prognosis of metastatic breast cancer subtypes: The hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Research Treatment, 3, 507–514.CrossRef Lobbezoo, D. J. A., Van Kampen, R. J. W., Voogd, A. C., Dercksen, M. W., Van den Berkmortel, F., Smilde, T. J., et al. (2013). Prognosis of metastatic breast cancer subtypes: The hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Research Treatment, 3, 507–514.CrossRef
go back to reference National Comprehensive Cancer Network (NCCN). (2017). Distress, supportive care book. (1st ed.). Plymouth Meeting, PA: NCCN. National Comprehensive Cancer Network (NCCN). (2017). Distress, supportive care book. (1st ed.). Plymouth Meeting, PA: NCCN.
go back to reference Nijnatten, T. J., Schipper, R. J., Lobbes, M. B., Nelemans, P. J., Beets-Tan, R. G., & Smidt, M. L. (2015). The diagnostic performance of sentinel lymph node biopsy in pathologically confirmed node positive breast cancer patients after neoadjuvant systemic therapy: A systematic review and meta-analysis. European Journal of Surgical Oncology, 10, 1278–1287.CrossRef Nijnatten, T. J., Schipper, R. J., Lobbes, M. B., Nelemans, P. J., Beets-Tan, R. G., & Smidt, M. L. (2015). The diagnostic performance of sentinel lymph node biopsy in pathologically confirmed node positive breast cancer patients after neoadjuvant systemic therapy: A systematic review and meta-analysis. European Journal of Surgical Oncology, 10, 1278–1287.CrossRef
go back to reference Raphael, D. B., Ter Stege, J. A., Russell, N. S., Boersma, L. J., & Van der Weijden, T. (2020). What do patients and health care professionals view as important attributes in radiotherapy decisions? Input for a breast cancer patient decision aid. The Breast, 49, 149–156.CrossRef Raphael, D. B., Ter Stege, J. A., Russell, N. S., Boersma, L. J., & Van der Weijden, T. (2020). What do patients and health care professionals view as important attributes in radiotherapy decisions? Input for a breast cancer patient decision aid. The Breast, 49, 149–156.CrossRef
go back to reference Roozendaal, L. M., Goorts, B., Klinkert, M., Kyemeulen, K. B. M. I., De Vries, B., Strobbe, L. J. A., et al. (2016). Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy. Breast Cancer Research and Treatment, 3, 517–525.CrossRef Roozendaal, L. M., Goorts, B., Klinkert, M., Kyemeulen, K. B. M. I., De Vries, B., Strobbe, L. J. A., et al. (2016). Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy. Breast Cancer Research and Treatment, 3, 517–525.CrossRef
go back to reference Schröder, C., Van der Woude, G., Jansen, L., Martens, J., Wesseling, J., & Sonke, G. (2017). Herkennen van inflammatoir mammacarcinoom. Huisarts En Wetenschap, 8, 404–406.CrossRef Schröder, C., Van der Woude, G., Jansen, L., Martens, J., Wesseling, J., & Sonke, G. (2017). Herkennen van inflammatoir mammacarcinoom. Huisarts En Wetenschap, 8, 404–406.CrossRef
go back to reference Speers, C., & Pierce, L.J. (2016). Postoperative radiotherapy after breast-conserving surgery for early-stage breast cancer: A review. JAMA Oncology, 1075–1082. Speers, C., & Pierce, L.J. (2016). Postoperative radiotherapy after breast-conserving surgery for early-stage breast cancer: A review. JAMA Oncology, 1075–1082.
go back to reference Van Bommel, A., Sponk, P., Mureau, M., Siesling, S., Smorenburg, C. Tollenaar, R, Vrancken Peeters, M.J., & Van Dalen, T. (2019). Breast-contour-preserving procedure as a multidisciplinary parameter of esthetic outcome in breast cancer treatment in the Netherlands. Annals of Surgical Oncology, 6, 1704–1711. Van Bommel, A., Sponk, P., Mureau, M., Siesling, S., Smorenburg, C. Tollenaar, R, Vrancken Peeters, M.J., & Van Dalen, T. (2019). Breast-contour-preserving procedure as a multidisciplinary parameter of esthetic outcome in breast cancer treatment in the Netherlands. Annals of Surgical Oncology, 6, 1704–1711.
go back to reference Van Roozendaal, L. M., De Wilt, J. H. W., Van Dalen, T., Van der Hage, J. A., Strobbe, L. J. A., Boersma, L. J., et al. (2015). The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy: A Dutch randomized controlled multicentre trial (BOOG 2013–07). BMC Cancer,15, 610–610. Van Roozendaal, L. M., De Wilt, J. H. W., Van Dalen, T., Van der Hage, J. A., Strobbe, L. J. A., Boersma, L. J., et al. (2015). The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy: A Dutch randomized controlled multicentre trial (BOOG 2013–07). BMC Cancer,15, 610–610.
go back to reference Whelan, T. J., Pignol, J. P., Levine, M. N., Julian, J. A., MacKenzie, R., Parpia, S., et al. (2010). Long-term results of hypofractionated radiation therapy for breast cancer. New England Journal of Medicine, 6, 513–520.CrossRef Whelan, T. J., Pignol, J. P., Levine, M. N., Julian, J. A., MacKenzie, R., Parpia, S., et al. (2010). Long-term results of hypofractionated radiation therapy for breast cancer. New England Journal of Medicine, 6, 513–520.CrossRef
Metagegevens
Titel
Mammacarcinoom
Auteurs
C. M. R. Haekens
M. V. C. Widdershoven, MANP
Dr. E. M. Heuts
Copyright
2021
Uitgeverij
Bohn Stafleu van Loghum
DOI
https://doi.org/10.1007/978-90-368-2645-7_24